Skip to content

Zalcitabine

FDA-approved product (tablet, oral), marketed as Hivid.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Zalcitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF03

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Zalcitabine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zalcitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

    NCT00095121 · start 2004-06

    Registered record
    Registry ID
    NCT00095121
    Conditions
    Chronic Hepatitis B
    Interventions
    Placebo (PLB); Adefovir Dipivoxil (ADV); Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    2010-04
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionPlacebo (PLB); Adefovir Dipivoxil (ADV); Lamivudine
    PhasePhase 3
    Registry statusCompleted
  • A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

    NCT00650637 · start 2003-01

    Registered record
    Registry ID
    NCT00650637
    Conditions
    Diarrhea
    Interventions
    Calcium Carbonate; nelfinavir; lamivudine; loperamide; Calcium carbonate not administered; nelfinavir; lamivudine + zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2003-01
    Completion
    2003-08
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhea
    InterventionCalcium Carbonate; nelfinavir; lamivudine; loperamide +3 more
    PhasePhase 3
    Registry statusTerminated
  • Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

    NCT00158405 · start 2002-12

    Registered record
    Registry ID
    NCT00158405
    Conditions
    HIV Infections
    Interventions
    Structured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV); Ritonavir (NRV); Indinavir (IDV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-12
    Completion
    2006-12
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionStructured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV) +2 more
    PhasePhase 3
    Registry statusCompleted
  • Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

    NCT00140725 · start 2000-04

    Registered record
    Registry ID
    NCT00140725
    Conditions
    Chronic Hepatitis B
    Interventions
    Lamivudine plus Polyethylene glyco-interferon alfa-2b; Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-04
    Completion
    Not recorded
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionLamivudine plus Polyethylene glyco-interferon alfa-2b; Lamivudine
    PhasePhase 3
    Registry statusCompleted
  • Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

    NCT02181933 · start 1999-04

    Registered record
    Registry ID
    NCT02181933
    Conditions
    HIV Infections
    Interventions
    Nevirapine; Zidovudine (ZDV); Lamivudine (3TC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-04
    Completion
    Not recorded
    Enrolment
    2,648

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine; Zidovudine (ZDV); Lamivudine (3TC)
    PhasePhase 3
    Registry statusCompleted
  • (Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC

    NCT00000679

    Registered record
    Registry ID
    NCT00000679
    Conditions
    HIV Infections
    Interventions
    Zidovudine; Zalcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine; Zalcitabine
    PhasePhase 2
    Registry statusCompleted
  • A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease

    NCT00000719

    Registered record
    Registry ID
    NCT00000719
    Conditions
    HIV Infections
    Interventions
    Zidovudine; Zalcitabine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1995-02
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine; Zalcitabine
    PhaseNot applicable
    Registry statusCompleted
  • A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

    NCT00000754

    Registered record
    Registry ID
    NCT00000754
    Conditions
    HIV Infections
    Interventions
    Interferon alfa-2a; Zidovudine; Zalcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1995-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionInterferon alfa-2a; Zidovudine; Zalcitabine
    PhasePhase 2
    Registry statusCompleted
  • A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)

    NCT00000781

    Registered record
    Registry ID
    NCT00000781
    Conditions
    HIV Infections
    Interventions
    Nevirapine; Zidovudine; Zalcitabine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1996-09
    Enrolment
    1,292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine; Zidovudine; Zalcitabine; Didanosine
    PhasePhase 2
    Registry statusCompleted
  • A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

    NCT00000918

    Registered record
    Registry ID
    NCT00000918
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir; Efavirenz; Saquinavir; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-02
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir +6 more
    PhasePhase 2
    Registry statusCompleted
  • A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma

    NCT00000954

    Registered record
    Registry ID
    NCT00000954
    Conditions
    Sarcoma, Kaposi; HIV Infections
    Interventions
    Bleomycin sulfate; Vincristine sulfate; Doxorubicin hydrochloride; Zalcitabine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1996-09
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma, Kaposi; HIV Infections
    InterventionBleomycin sulfate; Vincristine sulfate; Doxorubicin hydrochloride; Zalcitabine +1 more
    PhasePhase 1
    Registry statusCompleted
  • A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)

    NCT00000978

    Registered record
    Registry ID
    NCT00000978
    Conditions
    HIV Infections
    Interventions
    Zidovudine; Zalcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine; Zalcitabine
    PhasePhase 1
    Registry statusCompleted
  • Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

    NCT00002109

    Registered record
    Registry ID
    NCT00002109
    Conditions
    HIV Infections
    Interventions
    Thymopentin; Stavudine; Zidovudine; Zalcitabine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionThymopentin; Stavudine; Zidovudine; Zalcitabine +1 more
    PhasePhase 3
    Registry statusCompleted
  • A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

    NCT00002183

    Registered record
    Registry ID
    NCT00002183
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate; Amprenavir; Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate; Amprenavir; Lamivudine; Zidovudine
    PhasePhase 1
    Registry statusCompleted
  • An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

    NCT00002265

    Registered record
    Registry ID
    NCT00002265
    Conditions
    HIV Infections
    Interventions
    Zalcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZalcitabine
    PhasePhase 2
    Registry statusCompleted